Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK 0679

Known as: MK-0679, MK-679 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
BACKGROUND Cysteinyl leukotrienes (CysLTs) play a major role in the pathogenic changes of airway inflammation in asthma treatment… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2000
Highly Cited
2000
Cysteinyl leukotrienes (LTs), including LTC(4), LTD(4), and LTE(4), are well known to induce bronchoconstriction and increase… Expand
Review
1997
Review
1997
Asthma is a chronic inflammatory disease that is associated with widespread but variable airflow obstruction. The mechanisms that… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
1996
1996
Background The two main features of asthtna are bronchial hyperresponsiveness and inflammation. The inflammatory response in… Expand
1995
1995
Verlukast (MK-0679) is a potent leukotriene D4 antagonist that was under development for the treatment of bronchial asthma. A… Expand
Highly Cited
1993
Highly Cited
1993
Drugs which block the action or formation of the cysteinyl leukotrienes (LTC4, LTD4 and LTE4) inhibit asthmatic responses evoked… Expand
Highly Cited
1993
Highly Cited
1993
BACKGROUND--The cysteinyl leukotrienes (LTC4, LTD4, and LTE4) have been shown to mediate airway obstruction evoked by several… Expand
1993
1993
Descriptive studies suggest an association between the release of the cysteinyl leukotrienes and clinical asthma. To help clarify… Expand
1992
1992
The safety, tolerability and bronchodilator properties of inhaled verlukast (MK-0679), a new potent and selective LTD4-receptor… Expand
1991
1991
Verlukast (MK-679) (3-[(3-(2-(7-chloro-2-quinolinyl)-(E)-ethenyl)phenyl)[3-(dimethylamino)- 3- oxopropyl)thio)methyl)-thio… Expand